Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.

Source:http://linkedlifedata.com/resource/pubmed/id/17035318

Download in:

View as

General Info

PMID
17035318